Which has stronger valuation & earnings, ONCY or JSPR?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A

Is ONCY or JSPR more profitable?

Oncolytics Biotech's return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A N/A -442.99% Jasper Therapeutics N/A -884.17% -143.83%

Which has preferable valuation and earnings, JSPR or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A PDS Biotechnology N/A N/A -$34.50M -$0.64 N/A

Is JSPR or PDSB more profitable?

PDS Biotechnology's return on equity of -708.18% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% PDS Biotechnology N/A -708.18% -136.50%

Do analysts prefer XBIT or JSPR?

Jasper Therapeutics has a consensus target price of $7.33, indicating a potential upside of 1,309.71%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has preferable earnings & valuation, XBIT or JSPR?

XBiotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.48 N/A Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A

Is XBIT or JSPR more profitable?

XBiotech's return on equity of -31.62% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% Jasper Therapeutics N/A -884.17% -143.83%

Do analysts recommend APLM or JSPR?

Jasper Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 1,309.71%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has preferable earnings and valuation, APLM or JSPR?

Apollomics has higher revenue and earnings than Jasper Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.08 -$10.94M N/A N/A Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A

Is APLM or JSPR more profitable?

Apollomics' return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Jasper Therapeutics N/A -884.17% -143.83%

Jasper Therapeutics (JSPR) Competitors

$0.52 -0.01 (-2.22%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$0.52 +0.00 (+0.54%)

As of 10/30/2026 07:43 PM Eastern

Compare

JSPR vs. ONCY, PDSB, XBIT, APLM, and GOSS

Should you buy Jasper Therapeutics stock or one of its competitors? Jasper Therapeutics's main competitors and comparable companies include Oncolytics Biotech (ONCY), PDS Biotechnology (PDSB), XBiotech (XBIT), Apollomics (APLM), and Gossamer Bio (GOSS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jasper Therapeutics compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Oncolytics Biotech has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the broader market.

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 4.7% of Oncolytics Biotech shares are held by company insiders. Comparatively, 3.9% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Oncolytics Biotech had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Oncolytics Biotech and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.79 beat Oncolytics Biotech's score of 1.25 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncolytics Biotech	Positive
Jasper Therapeutics	Very Positive

Oncolytics Biotech currently has a consensus target price of $5.00, suggesting a potential upside of 1,075.36%. Jasper Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,309.71%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Oncolytics Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Oncolytics Biotech's return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	N/A	-442.99%
Jasper Therapeutics	N/A	-884.17%	-143.83%

Summary

Jasper Therapeutics beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks.

How does Jasper Therapeutics compare to PDS Biotechnology?

Jasper Therapeutics (NASDAQ:JSPR) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

PDS Biotechnology's return on equity of -708.18% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
PDS Biotechnology	N/A	-708.18%	-136.50%

Jasper Therapeutics has a beta of 3.16, meaning that its share price is 216% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

PDS Biotechnology is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

In the previous week, PDS Biotechnology had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 2 mentions for PDS Biotechnology and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.79 equaled PDS Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Jasper Therapeutics	Very Positive
PDS Biotechnology	Very Positive

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Jasper Therapeutics currently has a consensus price target of $7.33, suggesting a potential upside of 1,309.71%. PDS Biotechnology has a consensus price target of $9.50, suggesting a potential upside of 559.72%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than PDS Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

PDS Biotechnology beats Jasper Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Jasper Therapeutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

XBiotech's return on equity of -31.62% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Jasper Therapeutics	N/A	-884.17%	-143.83%

55.7% of XBiotech shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 21.1% of XBiotech shares are held by company insiders. Comparatively, 3.9% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

XBiotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

XBiotech has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market.

Jasper Therapeutics has a consensus target price of $7.33, indicating a potential upside of 1,309.71%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, XBiotech had 3 more articles in the media than Jasper Therapeutics. MarketBeat recorded 4 mentions for XBiotech and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.79 beat XBiotech's score of 1.20 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
XBiotech	Positive
Jasper Therapeutics	Very Positive

Summary

XBiotech and Jasper Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Apollomics' return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Jasper Therapeutics	N/A	-884.17%	-143.83%

Apollomics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, suggesting that its share price is 216% more volatile than the broader market.

Jasper Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 1,309.71%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Apollomics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.79 beat Apollomics' score of 1.49 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Positive
Jasper Therapeutics	Very Positive

19.1% of Apollomics shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Apollomics has higher revenue and earnings than Jasper Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.08	-$10.94M	N/A	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

Summary

Jasper Therapeutics beats Apollomics on 7 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to Gossamer Bio?

Jasper Therapeutics (NASDAQ:JSPR) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Jasper Therapeutics has a beta of 3.16, suggesting that its share price is 216% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

Jasper Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Gossamer Bio	$48.47M	1.31	-$170.37M	-$56.00	N/A

Jasper Therapeutics presently has a consensus price target of $7.33, suggesting a potential upside of 1,309.71%. Gossamer Bio has a consensus price target of $256.00, suggesting a potential upside of 2,366.28%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Jasper Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by company insiders. Comparatively, 4.2% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jasper Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Gossamer Bio	-235.00%	N/A	-112.04%

In the previous week, Gossamer Bio had 3 more articles in the media than Jasper Therapeutics. MarketBeat recorded 4 mentions for Gossamer Bio and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.79 beat Gossamer Bio's score of 0.98 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Jasper Therapeutics	Very Positive
Gossamer Bio	Positive

Summary

Gossamer Bio beats Jasper Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JSPR vs. The Competition

Export

Metric	Jasper Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.31M	$4.14B	$7.78B	$12.45B
Dividend Yield	N/A	3.62%	2.49%	4.44%
P/E Ratio	-0.33	31.46	35.92	32.59
Price / Sales	N/A	16.38	8.71	5.62
Price / Cash	N/A	23.13	21.13	23.08
Price / Book	3.47	4.44	4.90	4.09
Net Income	-$75.80M	-$22.12M	$3.50B	$381.88M
7 Day Performance	2.00%	0.38%	0.16%	-0.70%
1 Month Performance	-10.31%	-10.49%	-6.24%	-6.91%
1 Year Performance	-77.18%	-1.86%	-0.25%	-7.08%

Jasper Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JSPR Jasper Therapeutics	2.4595 of 5 stars	$0.52 -2.2%	$7.33 +1,309.7%	-76.1%	$17.31M	N/A	N/A	22	News Coverage Analyst Upgrade Gap Down
ONCY Oncolytics Biotech	1.9875 of 5 stars	$0.47 -1.7%	$5.00 +975.3%	-63.3%	$62.41M	N/A	N/A	29
PDSB PDS Biotechnology	2.6156 of 5 stars	$1.12 +4.7%	$9.00 +707.2%	+51.6%	$62.41M	N/A	N/A	21	Positive News Analyst Forecast Gap Down
XBIT XBiotech	1.9491 of 5 stars	$1.88 -2.8%	N/A	-21.7%	$57.17M	N/A	N/A	87	Insider Trade
APLM Apollomics	2.7789 of 5 stars	$19.80 -0.5%	N/A	+78.2%	$57.14M	$8.50M	N/A	15	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 10/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ONCY, PDSB, XBIT, APLM, and GOSS

How does Jasper Therapeutics compare to Oncolytics Biotech?

Summary

How does Jasper Therapeutics compare to PDS Biotechnology?

Summary

How does Jasper Therapeutics compare to XBiotech?

Summary

How does Jasper Therapeutics compare to Apollomics?

Summary

How does Jasper Therapeutics compare to Gossamer Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ONCY, PDSB, XBIT, APLM, and GOSS

How does Jasper Therapeutics compare to Oncolytics Biotech?

Which has more risk & volatility, ONCY or JSPR?

Which has stronger valuation & earnings, ONCY or JSPR?

Do institutionals & insiders believe in ONCY or JSPR?

Does the media prefer ONCY or JSPR?

Do analysts prefer ONCY or JSPR?

Is ONCY or JSPR more profitable?

Summary

How does Jasper Therapeutics compare to PDS Biotechnology?

Is JSPR or PDSB more profitable?

Which has more risk & volatility, JSPR or PDSB?

Which has preferable valuation and earnings, JSPR or PDSB?

Does the media favor JSPR or PDSB?

Do institutionals and insiders hold more shares of JSPR or PDSB?

Do analysts recommend JSPR or PDSB?

Summary

How does Jasper Therapeutics compare to XBiotech?

Is XBIT or JSPR more profitable?

Do insiders and institutionals believe in XBIT or JSPR?

Which has preferable earnings & valuation, XBIT or JSPR?

Which has more volatility and risk, XBIT or JSPR?

Do analysts prefer XBIT or JSPR?

Does the media favor XBIT or JSPR?

Summary

How does Jasper Therapeutics compare to Apollomics?

Is APLM or JSPR more profitable?

Which has more risk and volatility, APLM or JSPR?

Do analysts recommend APLM or JSPR?

Does the media prefer APLM or JSPR?

Do insiders & institutionals hold more shares of APLM or JSPR?

Which has preferable earnings and valuation, APLM or JSPR?

Summary

How does Jasper Therapeutics compare to Gossamer Bio?

Which has more volatility & risk, JSPR or GOSS?

Which has stronger valuation and earnings, JSPR or GOSS?

Do analysts rate JSPR or GOSS?

Do institutionals and insiders have more ownership in JSPR or GOSS?

Is JSPR or GOSS more profitable?

Does the media refer more to JSPR or GOSS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools